Glaukos

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Glaukos and other ETFs, options, and stocks.

About GKOS

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. 

CEO
Thomas William Burns
CEOThomas William Burns
Employees
995
Employees995
Headquarters
Aliso Viejo, California
HeadquartersAliso Viejo, California
Founded
1998
Founded1998
Employees
995
Employees995

GKOS Key Statistics

Market cap
6.90B
Market cap6.90B
Price-Earnings ratio
-77.36
Price-Earnings ratio-77.36
Dividend yield
Dividend yield
Average volume
1.10M
Average volume1.10M
High today
$125.04
High today$125.04
Low today
$119.86
Low today$119.86
Open price
$125.04
Open price$125.04
Volume
772.88K
Volume772.88K
52 Week high
$163.71
52 Week high$163.71
52 Week low
$73.16
52 Week low$73.16

Stock Snapshot

As of today, Glaukos(GKOS) shares are valued at $119.98. The company's market cap stands at 6.9B, with a P/E ratio of -77.36.

On 2026-01-23, Glaukos(GKOS) stock traded between a low of $119.86 and a high of $125.04. Shares are currently priced at $119.98, which is +0.1% above the low and -4.0% below the high.

Glaukos(GKOS) shares are trading with a volume of 772.88K, against a daily average of 1.1M.

In the last year, Glaukos(GKOS) shares hit a 52-week high of $163.71 and a 52-week low of $73.16.

In the last year, Glaukos(GKOS) shares hit a 52-week high of $163.71 and a 52-week low of $73.16.

GKOS News

Simply Wall St 16h
Glaukos Is Up 10.0% After Reaffirming 2026 Sales Guidance And Highlighting iDose TR Momentum

Glaukos Corporation recently reaffirmed its 2026 net sales guidance of US$600 million to US$620 million and released preliminary 2025 figures pointing to strong...

Glaukos Is Up 10.0% After Reaffirming 2026 Sales Guidance And Highlighting iDose TR Momentum
TipRanks 2d
Glaukos Advances Phase 3 Glaucoma Implant Trial, Keeping GKOS in Focus for Investors

Glaukos Corp. (GKOS) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Glaukos Corp. (GKOS) is running a new late-stage stud...

Analyst ratings

88%

of 16 ratings
Buy
87.5%
Hold
6.3%
Sell
6.3%

People also own

Based on the portfolios of people who own GKOS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.